monsitj Bristol-Myers Squibb, Inc. (NYSE:BMY) is in the health care sector and in the pharmaceutical industry. While not a factor in my analysis of the company, BMY is expected to have 2024 annual revenue of $45.85B and annual earnings per share of $6.83. BMY is also yielding a safe 4.43%. In this article I will outline why I think BMY is a speculative buy at this price. It is speculative because not all of my preferred parameters are in place yet as I will outline in the article. My investment thesis w ...

Core Insights - Three companies in the pharmaceuticals and healthcare sectors present significant investment opportunities due to their strategic growth initiatives and market positioning [1][2] Group 1: Bristol-Myers Squibb (BMY) - Bristol-Myers Squibb has enhanced its growth profile through strategic acquisitions, including RayzeBio, Mirati Therapeutics, and Karuna Therapeutics, which provide advanced platforms and pipeline assets [3] - The acquisition of Karuna Therapeutics supports the potential for multi-billion-dollar sales from KarXT, aimed at treating schizophrenia and Alzheimer's psychosis [3] - Strategic alliances, such as the one with SystImmune, provide unique technology and oncology resources, enhancing the company's market capabilities [4] Group 2: Walgreens Boots Alliance (WBA) - Walgreens Boots Alliance reported an 8.7% year-over-year increase in pharmacy comp sales in Q2 2024, driven by prescription volume growth and brand inflation [5] - The acquisition of Summit Health and collaboration with VillageMD have strengthened Walgreens Boots Alliance's healthcare service offerings [5][6] - Boots UK demonstrated resilience with a 3.2% year-over-year sales increase, supported by strategic initiatives and market share growth [6] Group 3: CVS Health (CVS) - CVS Health achieved $93.8 billion in consolidated Q4 revenues, reflecting an 11.9% year-over-year growth, and $357.8 billion in consolidated revenue for 2023, a 10.9% increase [7] - The Healthcare Benefits division reported approximately $27 billion in Q4 revenues, a significant rise of over 16% year-over-year, showcasing the segment's adaptability [7][8] - The Health Services segment generated over $49 billion in Q4 sales, indicating a growth of over 12% year-over-year, driven by strong pharmacy services and strategic acquisitions [8]

Bristol Myers (BMY) announced that a late-stage study on orally-administered Zeposia (ozanimod) in Crohn’s disease (CD) indication failed to achieve its primary endpoint.This late-stage study was the first of the two induction studies in the phase III YELLOWSTONE clinical program, which evaluated Zeposia in 600 adult patients with moderate to severe active CD over a 12-week treatment period. Initial results from the study showed that treatment with Zeposia failed to meet the primary endpoint of clinical rem ...

Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on researching new drugs. These drugs, being their products, are thus in development and thus the future revenue is not assured. The future revenue hinges on successful FDA approvals and the ability to actually sell the drug. As such, this industry is known for companies that tank 50% in just days following poor clinical resul ...

Bristol Myers Squibb (BMY) ended the recent trading session at $51.59, demonstrating a -0.56% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.32%. On the other hand, the Dow registered a gain of 0.68%, and the technology-centric Nasdaq increased by 0.2%.The biopharmaceutical company's shares have seen an increase of 1.91% over the last month, surpassing the Medical sector's gain of 0.88% and falling behind the S&P 500's gain of 5.11%.The investment community wi ...

Bristol Myers (BMY) announced that the European Commission (EC) has approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma.The therapy is now approved in the European Union (EU) in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.Abecma is already approved in the EU, Switzerland, Japan, the United Kingdom and Israel for adult patients with triple-class exposed relapsed or refractory multiple myeloma after three to four or more prior lines of ...

PRINCETON, N.J.--(BUSINESS WIRE)--Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “SO, Have You Found It?” campaign. This initiative spotlights the resilience of around two million Americans with moderate to severe plaque psoriasis, aiming to amplify their voices, underscoring the strength of their inner vibe, the “it” factor that makes someone uniquely them.i The campaign signifies a shift in dialogue from the challenges associated with ...

Bristol Myers Squibb (BMY) and partner 2seventy bio, Inc (TSVT) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor of Abecma’s (idecabtagene vicleucel) benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM).Abecma is a chimeric antigen receptor (CAR) T-cell therapy, already indicated for adult patients with triple-class exposed RRMM after four or more prior lines of treatment, including an immunomodulatory agent, a proteasome i ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion. "This acquisition recognizes the enormous potential of KarXT to help millions of ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”). “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, B ...